Swedish Orphan Biovitrum AB (publ)
STO:SOBI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Swedish Orphan Biovitrum AB (publ)
Capital Expenditures
Swedish Orphan Biovitrum AB (publ)
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Capital Expenditures
-kr2.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
24%
|
CAGR 10-Years
-49%
|
|
Biogaia AB
STO:BIOG B
|
Capital Expenditures
-kr48.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Hansa Biopharma AB
STO:HNSA
|
Capital Expenditures
kr134k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bonesupport Holding AB
STO:BONEX
|
Capital Expenditures
-kr7.6m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
Vitrolife AB
STO:VITR
|
Capital Expenditures
-kr134m
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
N/A
|
|
BioArctic AB
STO:BIOA B
|
Capital Expenditures
-kr7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures?
Capital Expenditures
-2.4B
SEK
Based on the financial report for Mar 31, 2024, Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures amounts to -2.4B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-49%
Over the last year, the Capital Expenditures growth was 47%. The average annual Capital Expenditures growth rates for Swedish Orphan Biovitrum AB (publ) have been 15% over the past three years , 24% over the past five years , and -49% over the past ten years .